Enhe Biotechnology
恩和生物
Enhe Biotechnology (恩和生物, also known as Bota Bio) is a global synthetic biology company founded by CEO Cheryl Cui, a Harvard-MIT Medical Engineering and Biophysics PhD who launched the firm with roughly 200 employees and began industrializing in 2023 . The company develops bioactive ingredients for cosmetics and biomedicine, combining AI with synthetic biology to produce customized functional raw materials . In May 2025, it became the first synthetic biology firm to secure a strategic partnership with cosmetics group Proya, focused on AI-driven ingredient innovation and green manufacturing . Source Code Capital and 5Y Capital are among its backers .
AI-generated — may contain errors, please verify.
Coverage
Bota Bio Enhe Biotechnology partners with Proya, becoming first synthetic biology company to secure strategic partnership with Proya
The beginning of a miracle often lies within the thing itself | 5Y News Monthly
The big news from last month.
Success is rarely replicable; what matters is finding your own path | 5Y View x Bota Bio x METiS Pharmaceuticals
Cross-disciplinary methodology for entrepreneurship.
September, Sprinting on the Cloud | 5Y News Monthly
The big news from last month.
"The Tech + Biotech" Crossover: A New Investment Consensus on Convergent Innovation
Professional, systematic, and patient for the long haul.
Source Code Capital closes fifth RMB fund, raising over 7 billion yuan to back tech innovation and SMEs
Invest early, invest small, invest in tech
Soluble Microneedle Technology Company Youwei Biology Completes Tens of Millions of Yuan in Series A Financing Led by Source Code Capital
Effortless, painless drug delivery through a simple patch application.
Source Code Capital portfolio company "Lingkong Tianxing" announces completion of over 300 million yuan Series A funding round, with existing shareholder Source Code Capital continuing to increase its stake
The only high-tech enterprise in China engaged in commercial hypersonic flight technology.
Chemical.AI, an intelligent chemical synthesis platform, announced the completion of a nearly $15 million Series A+ funding round led by Source Code Capital.
Dedicated to solving new drug synthesis problems through artificial intelligence and chemical big data
Source Code Capital portfolio company Silicon Integrated announced the completion of a Series C financing round of several hundred million yuan. Source Code Capital was an investor in the company's Series B round.
Secured strategic investments from three major smartphone brands
As Fierce as August | 5Y News Monthly
The big news from last month.
5Y News | Synthetic Biology Company Bota Bio Raises Over $100 Million to Accelerate Efficient Design and Scaled Production of Bio-based Products
5Y Capital continues to pay close attention to emerging technologies at the intersection of information science and life sciences.
Synthetic biology company Bota Bio (Enhe Biotechnology) announced the completion of a Series B funding round exceeding $100 million, with existing shareholder Source Code Capital continuing to increase its stake.
Accelerating the design and production of high-performance, sustainable products through synthetic biology.
